Alert on URGN: The scanners at HealthTechMovers.com, with the help of Tipranks.com, found the following stock rating has recently occurred regarding this top healthtech stock. HealthTechMovers.com keeps investors informed of trending healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more.
Tara Bancroft analyst at TD Cowen reiterates coverage on UroGen Pharma Ltd. (URGN) stock in the Healthcare sector with a Buy rating. TipRanks.com has Bancroft rated as a 4.5 star analyst with a 53% return on investment and a 31.5% success rate. Bancroft has not provided a price target.
TipRanks.com reports that UroGen Pharma Ltd. stock currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target for URGN's stock is $43.88. The target pricing ranges from a high forecast of $60 down to a low forecast of $22. UroGen Pharma Ltd. (URGN)’s stock last closing price was $19.20 which would put the average price target at 128.52% upside.
In addition, TradingView issued a rating for URGN's stock over the next month, Barchart.com has rating and Yahoo! Finance has a n/a short-term outlook. Remember, securities are volatile, so please do your own research on URGN stock.
Click here for the full story on URGN stock >>
TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
This article was pulled from healthtechmovers.com as they are an authority in the HealthTech Stock Sector. HealthTechMovers.com keeps investors informed of trending healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more.
MarketMoversTickers.com
MarketMoverTickers.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Tara Bancroft analyst at TD Cowen reiterates coverage on UroGen Pharma Ltd. (URGN) stock in the Healthcare sector with a Buy rating. TipRanks.com has Bancroft rated as a 4.5 star analyst with a 53% return on investment and a 31.5% success rate. Bancroft has not provided a price target.
TipRanks.com reports that UroGen Pharma Ltd. stock currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target for URGN's stock is $43.88. The target pricing ranges from a high forecast of $60 down to a low forecast of $22. UroGen Pharma Ltd. (URGN)’s stock last closing price was $19.20 which would put the average price target at 128.52% upside.
In addition, TradingView issued a rating for URGN's stock over the next month, Barchart.com has rating and Yahoo! Finance has a n/a short-term outlook. Remember, securities are volatile, so please do your own research on URGN stock.
Click here for the full story on URGN stock >>
TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
This article was pulled from healthtechmovers.com as they are an authority in the HealthTech Stock Sector. HealthTechMovers.com keeps investors informed of trending healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more.
MarketMoversTickers.com
MarketMoverTickers.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
